Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter M Irving

Showing results (161-170 of 195) with videos related to

Pageof 20
Sort By:
Inflammatory Bowel Diseases|March 9, 2024
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension StudyBruce E Sands, Geert D'Haens, David B Clemow, et al.
Gastroenterology|April 29, 2015
Interleukin 6 Increases Production of Cytokines by Colonic Innate Lymphoid Cells in Mice and Patients With Chronic Intestinal InflammationNick Powell, Jonathan W Lo, Paolo Biancheri, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 19, 2016
Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of ResultsGil Y Melmed, Peter M Irving, Jennifer Jones, et al.
Inflammatory Bowel Diseases|November 22, 2025
Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by AgeAdam S Faye, David T Rubin, Corey A Siegel, et al.
Gut|February 26, 2015
Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's diseaseJames B Canavan, Cristiano Scottà, Anna Vossenkämper, et al.
The Lancet. Gastroenterology & Hepatology|January 13, 2022
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectivesKonstantinos Papamichael, Waqqas Afif, David Drobne, et al.
Journal of Crohn'S & Colitis|May 24, 2022
Thromboprophylaxis Use in Paediatric Inflammatory Bowel Disease: An International RAND Appropriateness PanelFranco Torrente, Susanna Meade, Eric I Benchimol, et al.
Thorax|May 28, 2021
RAND appropriateness panel to determine the applicability of UK guidelines on the management of acute respiratory distress syndrome (ARDS) and other strategies in the context of the COVID-19 pandemicMark Griffiths, Susanna Meade, Charlotte Summers, et al.
Circulation. Heart Failure|November 22, 2021
Contemporary Management of Cardiogenic Shock: A RAND Appropriateness Panel ApproachAlastair G Proudfoot, Antonis Kalakoutas, Susanna Meade, et al.
Frontline Gastroenterology|August 26, 2017
Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centresMark A Samaan, Polychronis Pavlidis, Emma Johnston, et al.
Pageof 20

Showing results (161-170 of 195) with videos related to

Sort By:
Pageof 20
Inflammatory Bowel Diseases|March 9, 2024
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension StudyBruce E Sands, Geert D'Haens, David B Clemow, et al.
Gastroenterology|April 29, 2015
Interleukin 6 Increases Production of Cytokines by Colonic Innate Lymphoid Cells in Mice and Patients With Chronic Intestinal InflammationNick Powell, Jonathan W Lo, Paolo Biancheri, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 19, 2016
Appropriateness of Testing for Anti-Tumor Necrosis Factor Agent and Antibody Concentrations, and Interpretation of ResultsGil Y Melmed, Peter M Irving, Jennifer Jones, et al.
Inflammatory Bowel Diseases|November 22, 2025
Safety and Efficacy of Ozanimod in Patients With Moderately to Severely Active Ulcerative Colitis Stratified by AgeAdam S Faye, David T Rubin, Corey A Siegel, et al.
Gut|February 26, 2015
Developing in vitro expanded CD45RA+ regulatory T cells as an adoptive cell therapy for Crohn's diseaseJames B Canavan, Cristiano Scottà, Anna Vossenkämper, et al.
The Lancet. Gastroenterology & Hepatology|January 13, 2022
Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectivesKonstantinos Papamichael, Waqqas Afif, David Drobne, et al.
Journal of Crohn'S & Colitis|May 24, 2022
Thromboprophylaxis Use in Paediatric Inflammatory Bowel Disease: An International RAND Appropriateness PanelFranco Torrente, Susanna Meade, Eric I Benchimol, et al.
Thorax|May 28, 2021
RAND appropriateness panel to determine the applicability of UK guidelines on the management of acute respiratory distress syndrome (ARDS) and other strategies in the context of the COVID-19 pandemicMark Griffiths, Susanna Meade, Charlotte Summers, et al.
Circulation. Heart Failure|November 22, 2021
Contemporary Management of Cardiogenic Shock: A RAND Appropriateness Panel ApproachAlastair G Proudfoot, Antonis Kalakoutas, Susanna Meade, et al.
Frontline Gastroenterology|August 26, 2017
Vedolizumab: early experience and medium-term outcomes from two UK tertiary IBD centresMark A Samaan, Polychronis Pavlidis, Emma Johnston, et al.
Pageof 20